Related Experiment Video
Updated: Aug 16, 2025
Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling
Bärbel Schröfelbauer1,2, Patrick K Kimes3, Paige Hauke1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
Abstract:
Although antibodies targeting specific tumor-expressed antigens are the standard of care for some cancers, the identification of cancer-specific targets amenable to antibody binding has remained a bottleneck in development of new therapeutics. To overcome this challenge, we developed a high-throughput platform that allows for the unbiased, simultaneous discovery of antibodies and targets based on phenotypic binding profiles. Applying this platform to ovarian cancer, we identified a wide diversity of cancer targets including receptor tyrosine kinases, adhesion and migration proteins, proteases and proteins regulating angiogenesis in a single round of screening using genomics, flow cytometry, and mass spectrometry. In particular, we identified BCAM as a promising candidate for targeted therapy in high-grade serous ovarian cancers. More generally, this approach provides a rapid and flexible framework to identify cancer targets and antibodies.
Insights
We developed a new platform for discovering cancer targets and antibodies simultaneously. This approach identified BCAM as a potential therapeutic target for ovarian cancer.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Antibody-based cancer therapeutics rely on identifying specific tumor antigens.
- Discovering novel cancer targets for antibody development remains a significant challenge.
Purpose of the Study:
- To develop a high-throughput platform for unbiased, simultaneous discovery of cancer targets and antibodies.
- To identify novel therapeutic targets for ovarian cancer.
Main Methods:
- Utilized a phenotypic binding profile-based screening approach.
- Integrated genomics, flow cytometry, and mass spectrometry for target identification.
- Applied the platform to ovarian cancer models.
Main Results:
- Identified a diverse range of ovarian cancer targets, including receptor tyrosine kinases, adhesion/migration proteins, proteases, and angiogenesis regulators.
- BCAM was identified as a promising target for high-grade serous ovarian cancers.
- Demonstrated the platform's ability to discover multiple targets in a single screening round.
Conclusions:
- The developed platform offers a rapid and flexible framework for identifying cancer targets and therapeutic antibodies.
- BCAM represents a potential novel target for ovarian cancer therapy.
- This unbiased approach accelerates the development of targeted cancer treatments.
More Related Videos
15:17Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010